| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Febrile Neutropenia | 3 | 2023 | 16 | 2.140 |
Why?
|
| Syphilis, Congenital | 2 | 2025 | 9 | 1.730 |
Why?
|
| Anti-Bacterial Agents | 9 | 2025 | 833 | 1.520 |
Why?
|
| Bacteremia | 4 | 2022 | 107 | 1.420 |
Why?
|
| Hospitals, Pediatric | 3 | 2025 | 118 | 1.120 |
Why?
|
| Sepsis | 2 | 2023 | 382 | 1.110 |
Why?
|
| Penicillins | 1 | 2025 | 24 | 0.880 |
Why?
|
| Tertiary Care Centers | 3 | 2024 | 127 | 0.870 |
Why?
|
| Clostridium Infections | 3 | 2023 | 126 | 0.790 |
Why?
|
| Blood Culture | 2 | 2020 | 13 | 0.760 |
Why?
|
| Neoplasms | 3 | 2023 | 3168 | 0.740 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2023 | 70 | 0.730 |
Why?
|
| Hypotension | 1 | 2022 | 71 | 0.700 |
Why?
|
| Publishing | 1 | 2022 | 91 | 0.680 |
Why?
|
| Pandemics | 3 | 2022 | 873 | 0.670 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 284 | 0.670 |
Why?
|
| Public Health | 1 | 2022 | 152 | 0.670 |
Why?
|
| Child | 19 | 2025 | 7273 | 0.660 |
Why?
|
| Fever | 5 | 2022 | 121 | 0.610 |
Why?
|
| Infant, Newborn | 8 | 2025 | 2427 | 0.580 |
Why?
|
| Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.510 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2019 | 25 | 0.490 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 284 | 0.490 |
Why?
|
| Bacteria | 1 | 2020 | 508 | 0.480 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 85 | 0.470 |
Why?
|
| Humans | 46 | 2025 | 93132 | 0.450 |
Why?
|
| Cross Infection | 4 | 2023 | 149 | 0.440 |
Why?
|
| Retrospective Studies | 9 | 2025 | 10128 | 0.410 |
Why?
|
| Neutrophils | 3 | 2020 | 324 | 0.410 |
Why?
|
| Child, Preschool | 13 | 2025 | 3781 | 0.380 |
Why?
|
| Virulence Factors | 2 | 2010 | 113 | 0.380 |
Why?
|
| Leadership | 4 | 2021 | 149 | 0.370 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2009 | 5 | 0.360 |
Why?
|
| Hemolysin Proteins | 2 | 2009 | 32 | 0.360 |
Why?
|
| Infant | 7 | 2025 | 3156 | 0.360 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2024 | 95 | 0.350 |
Why?
|
| Bacterial Toxins | 2 | 2009 | 112 | 0.340 |
Why?
|
| Adolescent | 11 | 2025 | 9550 | 0.320 |
Why?
|
| Adhesins, Bacterial | 1 | 2010 | 36 | 0.320 |
Why?
|
| Bacterial Adhesion | 1 | 2010 | 83 | 0.320 |
Why?
|
| Proteoglycans | 1 | 2010 | 75 | 0.310 |
Why?
|
| Pregnancy | 4 | 2025 | 3128 | 0.300 |
Why?
|
| Membrane Transport Proteins | 1 | 2010 | 169 | 0.300 |
Why?
|
| Communicable Diseases | 1 | 2010 | 69 | 0.290 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 557 | 0.290 |
Why?
|
| Lung Diseases | 2 | 2009 | 282 | 0.290 |
Why?
|
| Chemokines, CXC | 1 | 2008 | 22 | 0.290 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 32 | 0.280 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2020 | 144 | 0.280 |
Why?
|
| Actinomycosis | 1 | 2008 | 12 | 0.270 |
Why?
|
| Syndecans | 1 | 2007 | 4 | 0.270 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 240 | 0.270 |
Why?
|
| HIV Infections | 1 | 2017 | 952 | 0.260 |
Why?
|
| United States | 8 | 2025 | 7581 | 0.260 |
Why?
|
| Drug Utilization | 2 | 2018 | 63 | 0.250 |
Why?
|
| Guideline Adherence | 2 | 2021 | 237 | 0.250 |
Why?
|
| Male | 17 | 2025 | 44355 | 0.250 |
Why?
|
| Infection Control | 4 | 2023 | 130 | 0.250 |
Why?
|
| Critical Care | 2 | 2022 | 442 | 0.240 |
Why?
|
| Shock, Septic | 2 | 2023 | 123 | 0.240 |
Why?
|
| Health Personnel | 2 | 2021 | 234 | 0.240 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 147 | 0.240 |
Why?
|
| Female | 17 | 2025 | 48542 | 0.230 |
Why?
|
| Appendicitis | 1 | 2006 | 64 | 0.230 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2005 | 1 | 0.230 |
Why?
|
| Paragonimiasis | 1 | 2005 | 1 | 0.230 |
Why?
|
| Health Information Systems | 1 | 2025 | 7 | 0.220 |
Why?
|
| Caregivers | 2 | 2025 | 171 | 0.220 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2024 | 9 | 0.210 |
Why?
|
| Personal Protective Equipment | 2 | 2021 | 38 | 0.210 |
Why?
|
| Child, Hospitalized | 1 | 2025 | 38 | 0.210 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 648 | 0.210 |
Why?
|
| Triage | 1 | 2025 | 131 | 0.200 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 67 | 0.200 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2023 | 24 | 0.190 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 109 | 0.190 |
Why?
|
| Inflammation | 2 | 2008 | 1049 | 0.180 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 85 | 0.180 |
Why?
|
| Aftercare | 1 | 2023 | 89 | 0.180 |
Why?
|
| Monocytes | 1 | 2023 | 214 | 0.180 |
Why?
|
| Critical Pathways | 1 | 2022 | 36 | 0.180 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2021 | 33 | 0.170 |
Why?
|
| Hand Hygiene | 1 | 2021 | 12 | 0.170 |
Why?
|
| Machine Learning | 1 | 2025 | 346 | 0.170 |
Why?
|
| Inpatients | 2 | 2021 | 341 | 0.170 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 59 | 0.170 |
Why?
|
| Burns | 1 | 2023 | 149 | 0.170 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 449 | 0.170 |
Why?
|
| Infliximab | 2 | 2019 | 162 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2025 | 1004 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2023 | 350 | 0.160 |
Why?
|
| Neutropenia | 1 | 2020 | 209 | 0.150 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 11 | 0.150 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 32 | 0.140 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 35 | 0.140 |
Why?
|
| Syndecan-1 | 2 | 2009 | 18 | 0.140 |
Why?
|
| Expert Testimony | 1 | 2018 | 34 | 0.140 |
Why?
|
| Logistic Models | 1 | 2022 | 1240 | 0.140 |
Why?
|
| Chagas Disease | 1 | 2018 | 4 | 0.140 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 24 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2022 | 373 | 0.140 |
Why?
|
| Leishmaniasis | 1 | 2017 | 5 | 0.130 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2017 | 16 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 888 | 0.130 |
Why?
|
| Directly Observed Therapy | 1 | 2017 | 5 | 0.130 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 7 | 0.130 |
Why?
|
| Health Resources | 1 | 2018 | 78 | 0.130 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 22 | 0.130 |
Why?
|
| Meglumine | 1 | 2017 | 36 | 0.130 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 30 | 0.130 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2017 | 27 | 0.130 |
Why?
|
| HIV Antibodies | 1 | 2017 | 38 | 0.120 |
Why?
|
| Drug Overdose | 1 | 2018 | 89 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1719 | 0.120 |
Why?
|
| Adult | 5 | 2025 | 27849 | 0.120 |
Why?
|
| Vancomycin | 1 | 2017 | 75 | 0.120 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2025 | 117 | 0.120 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 5 | 0.120 |
Why?
|
| Sorbitol | 1 | 2016 | 9 | 0.120 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 9 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 138 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 36 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 290 | 0.110 |
Why?
|
| Acute Disease | 1 | 2017 | 838 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 147 | 0.110 |
Why?
|
| Genotype | 1 | 2019 | 1866 | 0.110 |
Why?
|
| Social Media | 1 | 2016 | 111 | 0.110 |
Why?
|
| Education, Medical | 1 | 2016 | 227 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 940 | 0.100 |
Why?
|
| Epidermal Cyst | 1 | 2013 | 6 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 168 | 0.100 |
Why?
|
| Young Adult | 3 | 2020 | 6922 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3814 | 0.100 |
Why?
|
| Escherichia coli | 1 | 2016 | 562 | 0.100 |
Why?
|
| Meningitis | 1 | 2013 | 22 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 515 | 0.100 |
Why?
|
| Physician's Role | 1 | 2015 | 175 | 0.100 |
Why?
|
| Prognosis | 1 | 2020 | 3890 | 0.090 |
Why?
|
| Animals | 7 | 2010 | 27973 | 0.090 |
Why?
|
| Brain Diseases | 1 | 2013 | 172 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2015 | 347 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 2787 | 0.080 |
Why?
|
| Aspirin | 2 | 2014 | 164 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2010 | 726 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2014 | 249 | 0.070 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2009 | 20 | 0.070 |
Why?
|
| Chemokines | 1 | 2008 | 76 | 0.070 |
Why?
|
| Enterotoxins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Lung Injury | 1 | 2009 | 59 | 0.070 |
Why?
|
| Brain Abscess | 1 | 2007 | 8 | 0.070 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2007 | 16 | 0.070 |
Why?
|
| Leishmania | 2 | 2017 | 7 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1519 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2010 | 661 | 0.060 |
Why?
|
| Foreign Bodies | 1 | 2007 | 61 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2562 | 0.060 |
Why?
|
| Bronchi | 1 | 2007 | 224 | 0.060 |
Why?
|
| Risk Factors | 3 | 2023 | 5900 | 0.060 |
Why?
|
| Praziquantel | 1 | 2005 | 1 | 0.060 |
Why?
|
| Anthelmintics | 1 | 2005 | 6 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3431 | 0.050 |
Why?
|
| Chicago | 2 | 2019 | 1452 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2025 | 107 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1260 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 750 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2025 | 359 | 0.050 |
Why?
|
| Health Facilities | 1 | 2023 | 39 | 0.050 |
Why?
|
| Bandages | 1 | 2023 | 42 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2023 | 83 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2025 | 346 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2025 | 480 | 0.040 |
Why?
|
| Parents | 1 | 2025 | 292 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2025 | 418 | 0.040 |
Why?
|
| Child Care | 1 | 2021 | 4 | 0.040 |
Why?
|
| Hand Disinfection | 1 | 2021 | 18 | 0.040 |
Why?
|
| Personnel, Hospital | 1 | 2021 | 31 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2020 | 10 | 0.040 |
Why?
|
| Mice | 3 | 2009 | 12230 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 142 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 209 | 0.040 |
Why?
|
| Critical Illness | 1 | 2023 | 342 | 0.040 |
Why?
|
| Molecular Typing | 1 | 2019 | 19 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 181 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 12 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 57 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 165 | 0.030 |
Why?
|
| Medical Audit | 1 | 2018 | 41 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2019 | 231 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 159 | 0.030 |
Why?
|
| Mexico | 1 | 2018 | 72 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 389 | 0.030 |
Why?
|
| Epidemiologists | 1 | 2017 | 1 | 0.030 |
Why?
|
| Public Health Practice | 1 | 2017 | 11 | 0.030 |
Why?
|
| Public Health Administration | 1 | 2017 | 19 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 396 | 0.030 |
Why?
|
| Resource Allocation | 1 | 2017 | 64 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 2434 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 63 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 122 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 116 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 61 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 192 | 0.030 |
Why?
|
| Drug Costs | 1 | 2017 | 65 | 0.030 |
Why?
|
| Food Service, Hospital | 1 | 2016 | 4 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 655 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 913 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 820 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1318 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 329 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2015 | 51 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 916 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 748 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1925 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 924 | 0.030 |
Why?
|
| Viruses | 1 | 2015 | 64 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 494 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 212 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2014 | 122 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 42 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1909 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2014 | 175 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2705 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 679 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1697 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 3044 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 618 | 0.020 |
Why?
|
| Physicians | 1 | 2018 | 668 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2010 | 82 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1385 | 0.020 |
Why?
|
| Craniotomy | 1 | 2007 | 88 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 981 | 0.020 |
Why?
|
| Drainage | 1 | 2007 | 170 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2007 | 175 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1099 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1581 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 862 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 1945 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 9070 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 1359 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 2121 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1276 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 3497 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 27535 | 0.010 |
Why?
|